Processa Pharmaceuticals, Inc.
PCSAHealthcare|Biotechnology|US
$1.93
+0.09 (+4.89%)
DCF Value
$3.49
Cash / Share
$0.07
Financials
Financial Snapshot
Market Cap
$5.4M
Enterprise Value
$5.2M
Revenue (TTM)
$0.00
Net Income (TTM)
-$13.4M
Cash & Investments
$196.3K
Net Cash
$196.3K
Free Cash Flow (TTM)
-$11.5M
Operating CF (TTM)
-$12.0M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$196.3K
Quarterly Burn
$3.0M
Monthly Burn
$997.6K
Est. Runway
~0.1 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $3.2K | $2.8M | $1.7M | $691.5K | $15.4M | $16.5M | $6.5M | $4.7M | $1.2M | $5.5M | $196.3K | |
| Operating Cash Flow | -$43.2K | -$1.7M | -$3.7M | -$2.8M | -$3.1M | -$8.7M | -$9.6M | -$8.1M | -$11.2M | -$11.4M | -$12.0M | |
| Free Cash Flow | -$67.0K | -$1.7M | -$3.7M | -$2.8M | -$3.1M | -$8.7M | -$9.6M | -$8.1M | -$11.2M | -$11.4M | -$11.5M | |
| Capital Expenditure | -$23.8K | -$20.6K | -$20.5K | $0.00 | -$4.00 | $0.00 | $3.00 | -$2.8K | -$3.2K | -$5.00 | $500.0K | |
| Financing Cash Flow | $15.0K | $2.4M | $2.6M | $1.7M | $17.9M | $9.8M | -$388.8K | $6.3M | $7.7M | $16.6M | $6.4M |
R&D Spending
R&D (TTM)
$6.2M
R&D Intensity
—
R&D Growth vs Prior
-20.2%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $6.6K | $926.1K | $3.1M | $2.3M | $11.1M | $6.9M | $10.7M | $5.8M | $7.3M | $7.8M | $6.2M | |
| R&D % of Revenue | 131.2% | — | — | — | — | — | — | — | — | — | — | |
| SG&A | $384.5K | $876.3K | $1.4M | $1.6M | $3.2M | $4.7M | $8.7M | $5.7M | $4.8M | $6.2M | $6.6M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $1.4K | $0.00 | $0.00 | $0.00 | $882.1K | $0.00 | $874.0K | $0.00 | $0.00 | $0.00 | $301.00 | |
| Gross Profit | $3.6K | -$1.9K | -$630.1K | -$877.9K | -$882.1K | $0.00 | -$874.0K | $0.00 | $0.00 | $0.00 | -$301.00 | |
| R&D | $6.6K | $926.1K | $3.1M | $2.3M | $11.1M | $6.9M | $10.7M | $5.8M | $7.3M | $7.8M | $6.2M | |
| SG&A | $384.5K | $876.3K | $1.4M | $1.6M | $3.2M | $4.7M | $8.7M | $5.7M | $4.8M | $6.2M | $6.6M | |
| Operating Income | -$1.9M | -$1.8M | -$4.5M | -$3.9M | -$15.1M | -$12.1M | -$20.3M | -$11.5M | -$12.1M | -$14.0M | -$12.9M | |
| Interest Expense | $245.4K | $35.7K | $161.2K | $36.7K | $281.1K | $362.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.0K | |
| Pretax Income | -$337.2K | -$1.9M | -$4.7M | -$4.0M | -$15.4M | -$12.0M | -$27.4M | -$11.1M | -$11.9M | -$13.6M | -$13.4M | |
| Net Income | -$336.0K | -$1.9M | -$3.8M | -$3.4M | -$19.0M | -$11.4M | -$27.4M | -$11.1M | -$11.9M | -$13.6M | -$13.4M | |
| EPS (Diluted) | -747.25 | -200.00 | -355.00 | -304.25 | -1269.25 | -373.00 | -851.19 | -212.00 | -96.75 | -10.36 | -5.60 | |
| EBITDA | -$90.4K | -$1.8M | -$3.9M | -$3.1M | -$14.3M | -$10.8M | -$26.6M | -$11.1M | -$11.8M | -$13.6M | -$13.4M | |
| Shares Out. (M) | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | 0.05 | 0.12 | 1.31 | 2.75 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.2K | $2.8M | $1.7M | $691.5K | $15.4M | $16.5M | $6.5M | $4.7M | $1.2M | $5.5M | $196.3K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $3.2K | $3.0M | $2.0M | $1.0M | $16.2M | $18.3M | $8.4M | $5.6M | $1.9M | $5.7M | $2.1M | |
| Total Assets | $3.2K | $3.0M | $13.2M | $10.9M | $25.2M | $26.5M | $8.6M | $5.8M | $3.2M | $7.8M | $2.1M | |
| Total Current Liabilities | $97.7K | $2.6M | $645.7K | $1.2M | $1.2M | $971.0K | $998.6K | $730.6K | $1.5M | $2.2M | $2.4M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $44.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $2.4M | $2.6M | $3.5M | $2.9M | $2.3M | $978.4K | $1.1M | $797.5K | $1.5M | $2.2M | $2.4M | |
| Stockholders' Equity | -$2.4M | $373.2K | $9.7M | $8.0M | $22.9M | $25.5M | $7.5M | $5.0M | $1.7M | $5.6M | -$317.3K | |
| Retained Earnings | -$15.3M | -$3.9M | -$7.6M | -$11.0M | -$25.4M | -$36.8M | -$64.2M | -$75.4M | -$87.2M | -$100.8M | -$107.4M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$43.2K | -$1.7M | -$3.7M | -$2.8M | -$3.1M | -$8.7M | -$9.6M | -$8.1M | -$11.2M | -$11.4M | -$12.0M | |
| Capital Expenditure | -$23.8K | -$20.6K | -$20.5K | $0.00 | -$4.00 | $0.00 | $3.00 | -$2.8K | -$3.2K | -$5.00 | $500.0K | |
| Free Cash Flow | -$67.0K | -$1.7M | -$3.7M | -$2.8M | -$3.1M | -$8.7M | -$9.6M | -$8.1M | -$11.2M | -$11.4M | -$11.5M | |
| Investing Cash Flow | $17.0K | $1.0M | -$22.3K | $0.00 | $0.00 | $0.00 | $0.00 | -$2.8K | -$3.2K | -$850.0K | -$1.2M | |
| Financing Cash Flow | $15.0K | $2.4M | $2.6M | $1.7M | $17.9M | $9.8M | -$388.8K | $6.3M | $7.7M | $16.6M | $6.4M | |
| Issuance of Stock | $4.3M | $0.00 | $2.9M | $0.00 | $17.1M | $10.0M | $0.00 | $6.3M | $7.8M | $16.6M | $6.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | -$95.2K | -$64.4K | -$388.8K | $0.00 | -$15.9K | $0.00 | $1.4K | |
| Net Debt Issuance | $15.0K | $2.6M | $0.00 | $805.0K | $862.5K | $0.00 | $0.00 | $0.00 | -$5.2K | -$6.6K | $0.00 | |
| Stock Based Comp. | $6.7K | $0.00 | $74.1K | $510.5K | $2.7M | $3.4M | $8.8M | $1.1M | $629.5K | $857.5K | $386.9K | |
| Net Change in Cash | -$11.2K | $1.8M | -$1.1M | -$1.0M | $14.7M | $1.1M | -$10.0M | -$1.8M | -$3.5M | $4.3M | -$6.7M |
Dilution Tracker
Shares outstanding grew 8629.1% over 5 years — significant dilution
Shares Outstanding
3M
5-Year Share Growth
+8629.1%
Stock Issuance (TTM)
$6.4M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | 0.05 | 0.12 | 1.31 | 2.75 | |
| Change vs Prior % | — | 678.0% | 14.5% | 3.6% | 35.7% | 104.3% | 5.2% | 62.8% | 133.3% | 969.7% | 110.1% | |
| Stock Issuance | $4.3M | $0.00 | $2.9M | $0.00 | $17.1M | $10.0M | $0.00 | $6.3M | $7.8M | $16.6M | $6.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | -$95.2K | -$64.4K | -$388.8K | $0.00 | -$15.9K | $0.00 | $1.4K | |
| Stock Based Comp. | $6.7K | $0.00 | $74.1K | $510.5K | $2.7M | $3.4M | $8.8M | $1.1M | $629.5K | $857.5K | $386.9K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 72.4% | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin % | -38430.4% | — | — | — | — | — | — | — | — | — | — | |
| Net Margin % | -6719.6% | — | — | — | — | — | — | — | — | — | — | |
| EBITDA Margin % | -1808.3% | — | — | — | — | — | — | — | — | — | — | |
| FCF Margin % | -1339.6% | — | — | — | — | — | — | — | — | — | — | |
| ROE % | 14.3% | -497.5% | -38.8% | -41.9% | -83.0% | -44.8% | -367.1% | -222.9% | -698.6% | -243.2% | -394.2% | |
| ROA % | -10379.4% | -62.2% | -28.5% | -30.9% | -75.5% | -43.2% | -318.2% | -192.2% | -367.0% | -173.6% | -649.3% | |
| ROIC % | -123.9% | -63.0% | -30.3% | -31.6% | -58.5% | -45.4% | -263.1% | -222.9% | -681.0% | -250.8% | 4051.8% | |
| R&D / Revenue % | 131.2% | — | — | — | — | — | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -95.6% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 129.1% | -151.5% | -33685.1% | -39.3% | -0.5% | 100.0% | 0.0% | 100.0% | 0.0% | 0.0% | |
| Operating Income | -171.4% | 6.2% | -151.0% | 13.0% | -284.6% | 19.8% | -67.0% | 43.4% | -5.2% | -16.1% | |
| Net Income | 90.0% | -452.5% | -102.8% | 10.8% | -467.0% | 40.0% | -140.0% | 59.4% | -6.6% | -14.5% | |
| EPS (Diluted) | 90.0% | 73.2% | -77.5% | 14.3% | -317.2% | 70.6% | -128.2% | 75.1% | 54.4% | 89.3% | |
| Operating Cash Flow | 95.0% | -3729.9% | -124.1% | 25.8% | -14.3% | -177.3% | -10.2% | 16.1% | -39.5% | -1.2% | |
| Free Cash Flow | 92.3% | -2401.2% | -122.6% | 26.2% | -14.3% | -177.3% | -10.2% | 16.0% | -39.5% | -1.2% | |
| R&D Expense | -77.6% | 14021.9% | 233.1% | -24.8% | 377.3% | -37.9% | 55.7% | -45.8% | 25.3% | 7.4% | |
| SG&A Expense | -59.3% | 127.9% | 64.3% | 12.2% | 96.8% | 47.6% | 85.1% | -34.8% | -15.5% | 29.2% | |
| Total Assets | -96.9% | 92051.4% | 343.0% | -17.6% | 131.7% | 5.0% | -67.4% | -32.9% | -44.2% | 142.0% | |
| Book Value / Share | 0.0% | 102.0% | 2170.3% | -20.3% | 110.9% | -45.6% | -72.1% | -59.0% | -85.4% | -69.3% | |
| Debt | 18.0% | 51.9% | -90.6% | 346.9% | -68.1% | -76.1% | 192.4% | -34.4% | -51.2% | -100.0% | |
| Diluted Shares | 0.0% | 678.0% | 14.5% | 3.6% | 35.7% | 104.3% | 5.2% | 62.8% | 133.3% | 969.7% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-16.73
10Y Low / Med / High0.68 / 2.37 / 384.34
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$3.49
Cash / Share
$0.07
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1.17 | -77.00 | -35.49 | -29.58 | -2.60 | -6.57 | -0.65 | -0.79 | -0.23 | -0.28 | -0.34 | |
| P/S Ratio | 209.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -0.45 | 384.34 | 13.85 | 12.41 | 2.16 | 2.95 | 2.37 | 1.76 | 1.59 | 0.68 | -16.73 | |
| EV/EBITDA | -29.38 | -79.66 | -34.27 | -31.98 | -2.40 | -5.44 | -0.43 | -0.38 | -0.13 | 0.13 | -0.39 | |
| EV/Revenue | 531.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-92.92
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $10.0M | $10.4M | $53.1M |
| Net Income | -$7.9M | -$6.9M | -$7.2M |
| EPS | $-6.00 | $-5.25 | $-5.50 |
| # Analysts (EPS) | 1 | 1 | 1 |